29 related articles for article (PubMed ID: 3090208)
1. A phase I trial of recombinant gamma interferon in patients with cancer.
Foon KA; Sherwin SA; Abrams PG; Stevenson HC; Holmes P; Maluish AE; Oldham RK; Herberman RB
Cancer Immunol Immunother; 1985; 20(3):193-7. PubMed ID: 3933818
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients.
Boue F; Pastran Z; Spielmann M; Le Chevalier T; Subirana R; Sevin D; Paoletti C; Brandely M; Avril MF; Sancho-Garnier H
Cancer Immunol Immunother; 1990; 32(1):67-70. PubMed ID: 2126985
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours.
Wagstaff J; Smith D; Nelmes P; Loynds P; Crowther D
Cancer Immunol Immunother; 1987; 25(1):54-8. PubMed ID: 3109738
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and biological activity in subcutaneous long-term administration of recombinant interferon-gamma in cancer patients.
Digel W; Zahn G; Heinzel G; Porzsolt F
Cancer Immunol Immunother; 1991; 34(3):169-74. PubMed ID: 1756534
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer therapy with TNFα and IFNγ: A comprehensive review.
Shen J; Xiao Z; Zhao Q; Li M; Wu X; Zhang L; Hu W; Cho CH
Cell Prolif; 2018 Aug; 51(4):e12441. PubMed ID: 29484738
[TBL] [Abstract][Full Text] [Related]
6. Interferon-γ-induced necrosis: an antitumor biotherapeutic perspective.
Balachandran S; Adams GP
J Interferon Cytokine Res; 2013 Apr; 33(4):171-80. PubMed ID: 23570383
[TBL] [Abstract][Full Text] [Related]
7. Antitumor response to recombinant murine interferon gamma correlates with enhanced immune function of organ-associated, but not recirculating cytolytic T lymphocytes and macrophages.
Black PL; Phillips H; Tribble HR; Pennington R; Schneider M; Talmadge JE
Cancer Immunol Immunother; 1993 Oct; 37(5):299-306. PubMed ID: 8402733
[TBL] [Abstract][Full Text] [Related]
8. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
De Mulder PH; Oosterhof G; Bouffioux C; van Oosterom AT; Vermeylen K; Sylvester R
Br J Cancer; 1995 Feb; 71(2):371-5. PubMed ID: 7841054
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of tumor cell growth by interferon-gamma is mediated by two distinct mechanisms dependent upon oxygen tension: induction of tryptophan degradation and depletion of intracellular nicotinamide adenine dinucleotide.
Aune TM; Pogue SL
J Clin Invest; 1989 Sep; 84(3):863-75. PubMed ID: 2503544
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of recombinant gamma interferon into liposomes enhances its ability to induce peritoneal macrophage antitoxoplasma activity.
Mellors JW; Debs RJ; Ryan JL
Infect Immun; 1989 Jan; 57(1):132-7. PubMed ID: 2491832
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma.
de Mulder PH; Debruyne FM; Franssen MP; Geboers AD; Strijk S; Reintjes AG; Doesburg WH; Damsma O
Cancer Immunol Immunother; 1990; 31(5):321-4. PubMed ID: 2115817
[TBL] [Abstract][Full Text] [Related]
12. Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma.
Quesada JR; Kurzrock R; Sherwin SA; Gutterman JU
J Biol Response Mod; 1987 Feb; 6(1):20-7. PubMed ID: 3104544
[TBL] [Abstract][Full Text] [Related]
13. [Phase I-II study of recombinant interferon gamma].
Adachi K; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Nakada H; Tada A; Yamazaki H; Mukaiyama T
Gan To Kagaku Ryoho; 1985 Jun; 12(6):1331-8. PubMed ID: 2988459
[TBL] [Abstract][Full Text] [Related]
14. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):149-53. PubMed ID: 8610639
[TBL] [Abstract][Full Text] [Related]
15. [Long-term results in the treatment of metastasizing kidney carcinoma using recombinant alpha-2 or gamma interferon].
Schneider AW; Otto U; Conrad S; Klosterhalfen H
Helv Chir Acta; 1990 Nov; 57(3):415-21. PubMed ID: 2125299
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
Rinehart JJ; Malspeis L; Young D; Neidhart JA
J Biol Response Mod; 1986 Aug; 5(4):300-8. PubMed ID: 3090208
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
Rinehart J; Malspeis L; Young D; Neidhart J
Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
